Discordance between EGFR Expression and Clinicopathologic Parameters of Colorectal Adenocarcinoma in Taiwan

10.4077/CJP.2012.BAA061

Wen-Chiuan Tsai；Chih-Kung Lin；Herng-Sheng Lee；Ann Chen；Shin Nieh；Cheng-Ping Yu；Chang-Chieh Wu；Shu-Wen Jao；Jong-Shiaw Jin

colorectal adenocarcinoma ； EGFR ； Ki67 ； p53 ； tissue microarray

The Chinese Journal of Physiology

55卷5期（2012 / 10 / 01）

352 - 360

英文

Dysregulation of epidermal growth factor receptor (EGFR) has been associated with colorectal cancer, but no evidence shows a relationship of EGFR expression to clinicopathological parameters in colorectal cancer in Taiwan. Immunohistochemical analysis of EGFR, Ki67, and p53 was performed in tissue microarray slides of 9 normal glandular tissues and 150 specimens including 49 well, 58 moderately, and 43 poorly differentiated colorectal adenocarcinomas. Differences in intensity of EGFR immunostaining and the percentages of Ki67 and p53 positive cells between normal and tumor specimens were evaluated using the Student t-test, one-way ANOVA, and linear regression analysis. Intensity of EGFR staining was weak and nuclear expression of Ki67 and p53 was scattered in all 9 control specimens. Expression of Ki67 and p53 but not EGFR was significantly higher in more advanced grades and TNM stages of colorectal adenocarcinoma than in normal controls. The percentages of Ki67 and p53 stained tumor cells were significantly higher in moderately (Ki67: 60.3 ± 6.5, p53: 47.6 ± 3.8) and poorly (Ki67: 61.8 ± 5.3, p53: 55.1 ± 4.1) differentiated tumor cells than in well differentiated (Ki67: 40.8 ± 4.4, p53: 39.8 ± 4.2) tumor cells. Additionally, the Ki67 and p53 staining intensity was also significantly correlated with the more advanced T, N and American Joint Committee on Cancer (AJCC) clinical stage of colorectal adenocarcinoma, suggesting their usefulness as biomarkers of colorectal adenocarcinoma progression. In conclusion, EGFR immunochemistry may not be a good method for pre-treatment evaluation of colorectal adenocarcinoma in Taiwan.

1. Aimes, R. T.,Zijlstra, A.,Hooper, J. D.,Ogbourne, S. M.,Sit, M. L.,Fuchs, S.,Gotley, D. C.,Quigley, J. P.,Antalis, T. M.(2003).Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis.Thromb. Hemost.,89,561-572.
2. Allegra, C. J.,Paik, S.,Colangelo, L. H.,Parr, A. L.,Kirsch, I.,Kim, G.,Klein, P.,Johnston, P. G.,Wolmark, N.,Wieand, H. S.(2003).Prognostic value of thymidylate synthase, Ki67, and p53 in patients with Dukes B and C colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study.J. Clin. Oncol.,21,241-250.
3. Arber, N.,Hibshoosh, H.,Yasui, W.,Neugut, A.I.,Hibshoosh, A.,Yao, Y.,Sgambato, A.,Yamamoto, H.,Shapira, I.,Rosenman, D.,Fabian, I.,Weinstein, I. B.,Tahara, E.,Holt, P. R.(1999).Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel.Cancer Epiderm. Biomar.,8,1101-1105.
4. Benaud, C. M.,Oberst, M.,Dictson, R. B.,Lin, C. Y.(2002).Deregulated activation of matriptase in breast cancer cells.Clin. Exp. Metastasis.,19,639-649.
5. Benaud, C.,Dickson, R. B.,Lin, C.Y.(2001).Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor.Eur. J. Biochem.,268,1439-1447.
6. Berenzi, A.,Benetti, A.,Bertalot, G.,Rodolfi, A.,Portolani, N.,Giulini, S. M.,Pulcini, G.,Vinco, A.,Tiberio, G.(1992).Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical application.Pathologica,84,155-163.
7. Bhargava, R.,Chen, B.,Klimstra, D. S.,Saltz, L. B.,Hedvat, C.,Tang, L. H.,Gerald, W.,Teruya-Feldstein, J.,Paty, P.B.,Qin, J.,Shia, J.(2006).Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.Cancer,106,1857-1862.
8. Cagir, B.,Nagy, M. W.,Topham, A.,Rakinic, J.,Fry, R. D.(1999).Adenosquamous carcinoma of the colon, rectum, and anus: epidemiology, distribution, and survival characteristics.Dis. Colon Rectum,42,258-263.
9. Cerottini, J. P.,Caplin, S.,Pampallona, S.,Givel, J. C.(1999).Prognostic factors in colorectal cancer.Oncol. Rep.,6,409-414.
10. D''Errico, A.,Garbisa, S.,Liotta, L. A.,Castronovo, V.,Stetler-Stevenson, W. G.,Grigioni, W. F.(1991).Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.Mod. Pathol.,4,239-246.
11. Ding, H. F.,Fisher, D. E.(1998).Mechanisms of p53-mediated apoptosis.Crit. Rev. Oncog.,9,83-98.
12. El-Zammar, O. A.,Zhang, S.,Katzenstein, A. L.(2009).Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.Diagn. Mol. Pathol.,18,133-137.
13. Favis, R.,Huang, J.,Gerry, N. P.,Culliford, A.,Paty, P.,Soussi, T.,Barany, F.(2004).Harmonized microarray/mutation scanning analysis of TP53 mutation in undissected colorectal tumors.Hum. Muta.,24,63-75.
14. Ferrara, N.(1995).The role of vascular endothelial growth factor in pathological angiogenesis.Breast Cancer Res. Treat.,36,127-137.
15. Folkman, J.(1990).What is the evidence that tumors are angiogenesis dependent?.J. Natl. Cancer Inst.,82,4-6.
16. Galizia, G.,Ferraraccio, F.,Lieto, E.,Orditura, M.,Castellano, P.,Imperatore, V.,Romano, C.,Vollaro, M.,Agostini, B.,Pignatelli, C.,De Vita, F.(2004).Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.Dis. Colon Rectum,47,1904-1914.
17. Gerdes, J.,Lemke, H.,Baisk, H.,Wacker, H. H.,Schwab, U.,Stein, H.(1984).Cell cycle analysis of the cell proliferation associated human nuclear antigen defined by the monoclonal antiboby Ki67.J. Immunol.,133,1710-1715.
18. Gervaz, P.,Cerottini, J. P.,Bouzourene, H.,Hahnloser, D.,Doan, C. L.,Benhattar, J.,Chaubert, P.,Secic, M.,Gillet, M.,Carethers, J. M.(2002).Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer.Surgery,131,190-197.
19. Goldstein, N. S.,Armin, M.(2001).Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system.Cancer,92,1331-1346.
20. Graziano, F.,Cascinu, S.(2003).Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke's B colorectal cancer patients: how much evidence is enough.Ann. Oncol.,14,1026-1038.
21. Hamilton, S. R.,Aaltonen, L. A.(2000).WHO classification of tumors: tumors of the digestive system.Lyon:IRAC.
22. Harris, C. C.(1996).Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.J. Natl. Cancer Inst. (Bathesda),88,1442-1455.
23. He, T. C.,Sparks, A. B.,Rago, C.,Hermeking, H.,Zawel, L.,da Costa, L. T.,Morin, P. J.,Vogelstein, B.,Kinzler, K. W.(1998).Identification of c-myc as a target of the APC pathway.Science,281,1509-1512.
24. Hu, D. N.,Hwang, S. M.,Lin, X. Z.,Yang, P. Y.,Tsai, C. H.,Huang, Q.,Huang, H. Y.,Hwang, M. H.(2007).Isolation and characterization of two novel colon cancer cell lines from Chinese patients.In Vitro Cell Dev. Biol. Anim.,43,105-108.
25. Kyzer, S.,Gordon, P. H.(1997).Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67.Dis. Colon Rectum,40,322-325.
26. Lam, J. S.,Belldegrum, A. S.,Figlin, R. A.(2004).Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy.Clin. Cancer Res.,10,6304s-6309s.
27. Levine, A. J.(1997).p53, the cellular gatekeeper for growth and division.Cell,88,323-331.
28. McKay, J. A.,Douglas, J. J.,Ross, V. G.,Curran, S.,Ahmed, F. Y.,Loane, J. F.,Murray, G. I.,McLeod, H. L.(2000).Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases.Clin. Cancer Res.,6,1113-1118.
29. McLeod, H. L.,Murray, G. I.(1999).Tumor markers of prognosis in colorectal cancer.Brit. J. Cancer,79,191-203.
30. Nasif, W. A.,El-Emshaty, H. M.,Tabll, A.,Elmasry, S. A.,Attallah, A. M.,Gad Elhak, N. A.(2004).Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.Hepatogastroenterology,51,1001-1006.
31. Nicholson, R. I.,Gee, J. M.,Harper, M. E.(2001).EGFR and cancer prognosis.Eur. J. Cancer,37,S9-S15.
32. Perletti, G.,Marras, E.,Dondi, D.,Osti, D.,Congiu, T.,Ferrarese, R.,de Eguileor, M.,Tashjian, A. H., Jr.(2005).p21(Waf1/Cip1) and p53 are downstream effectors of protein kinase C delta in tumor suppression and differentiation in human colon cancer cells.Int. J. Cancer,113,42-53.
33. Perrone, G.,Vincenzi, B.,Sanini, D.,Verzi, A.,Tonini, G.,Vetrani, A.,Rabitti, C.(2004).Correlation of p53 and bcl-2 expression with vascular growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer.Cancer Letters,208,227-234.
34. Petersen, S.,Thames, H.D.,Nieder, C.,Petersen, C.,Baumann, M.(2001).The results of colorectal cancer treatment by p53 status: a treatment-specific overview.Dis. Colon Rectum,44,322-334.
35. Potter, J. D.(1999).Colorectal cancer: moleculaes and population.J. Natl. Cancer Inst.,91,916-932.
36. Resnick, M. B.,Routhier, J.,Konlin, T.,Sabo, E.,Pricolo, V. E.(2004).Epidermal growth factor receptor, c-Met, β-Catinin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.Clin. Cancer Res.,10,3069-3075.
37. Salomon, D.S.,Brandt, R.,Ciardiello, F.,Normanno, N.(1995).Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev. Oncol. Hematol.,19,183-232.
38. Sasaki, S.,Masaki, T.,Umetani, N.,Futakawa, N.,Ando, H.,Muto, T.(1998).Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observations.Jpn. J. Clin. Oncol.,28,202-206.
39. Thomas, G. V.,Szigeti, K.,Murphy, M.,Draetta, G.,Pagano, M.,Loda, M.(1998).Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.Am. J. Pathol.,153,681-687.

1. Yang, Hui-Ju,Lee, Meng-Chih,Kao, Erl-Shyh,Hu, Chao-Chin,Cheng, Chun-Yuan(2014).Inhibitory Effects of Scutellarein on Proliferation of Human Lung Cancer A549 Cells through ERK and NFκB Mediated by the EGFR Pathway.中國生理學雜誌,57(4),182-187.